Muamar Amirullah

[Muamar Amirullah @muamarray]

Turyr2yfyrurieirj

[gigs - TapIn @OghieGigs]

Bang Do mungkin akan sulit meraih rekor top skor sepanjang masa Piala Dunia.

Baru 8 gol sepanjang 5 edisi piala dunia. Coba bandingin sama 16 gol milik Messi.

Namun ada satu rekor yang tidak akan bisa dipecahkan Messi dalam waktu dekat apabila Cristiano Ronaldo bisa cetak 1 gol aja di WC2026 ini yaitu rekor selalu mencetak gol di 6 edisi piala dunia.

Bang Dodo sejauh ini cetak gol di:
2006 - 1 gol vs 🇮🇷
2010 - 1 gol vs 🇰🇵
2014 - 1 gol vs 🇬🇭
2018 - 3 gol vs 🇪🇸, 1 gol vs 🇲🇦
2022 - 1 gol vs 🇬🇭

[Muamar Amirullah @muamarray]

@Alex_Inspira AI

[KDIGO @goKDIGO]

KDIGO is pleased to announce the publication of the 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD).

Read the news release: https://t.co/kXzi5xxCvK
Download the guideline: https://t.co/wA8RRI90j9
Read the guideline in Kidney International: https://t.co/VHIZL34ls8

The KDIGO 2024 CKD Guideline was co-chaired by @adeeralevin and @KidneysRU. The Executive Summary will be published in the April 2024 issue of @Kidney_Int.

“We are thrilled to publish this eagerly anticipated update, which comes during a transformative period in nephrology, offering new hope for people living with kidney disease," said Dr. Levin. “Recent advancements in GFR evaluation, risk prediction, and the arrival of novel treatments are poised to enhance CKD prognosis and management. We also hope the guideline’s emphasis on multidisciplinary teamwork, patient engagement, and a holistic, evidence-based approach to care will help catalyze positive change, resulting in more coordinated CKD care management worldwide. By integrating the latest evidence and expert consensus, we aim to empower healthcare professionals, and patients with actionable recommendations to optimize patient outcomes and enhance quality of life.”

“As Co-Chairs, we would like to recognize the outstanding efforts of the Guideline Work Group and extend our thanks to the Evidence Review Team from Johns Hopkins, without whom this guideline would not have been possible," said Dr. Stevens. "The Work Group was diverse, multinational, highly experienced, and exceptionally committed, and we are grateful for their contributions to both this guideline and to global nephrology.”

[Manual Of Medicine @ManualOMedicine]

@drteoa Nephron Map - Nephron Physiology

[EHJ Editor-in-Chief @ehj_ed]

The year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders:
https://t.co/IrW8AYfPhL

#CVD #diabetes #metabolism #EHJ #cardiotwitter @ESC_Journals @escardio

[ASN Publications @asnpublications]

Depression is prevalent in patients with CKD and is related to poor prognosis. This study found antidepressant treatment was associated with short-term adverse outcomes but not long-term outcomes in people with CKD and depression https://t.co/JneSqdc2C7

@jjcarrero1

[The Heart @ZHeart11768530]

🔴 #NephMadness 2024: Hyponatremia Correction

Are we focusing too much in the wrong risk factor (Na correction rate) for developing ODS and not paying enough attention to the other ones (hypoK, hypoP, alcohol use, malnutrition...)?
https://t.co/CuddddqTjj

[Nurse Hann, RN @NurseHann100]

BRONCHODILATORS

#nursing #nursingnotes

[Oren Gottfried, MD @OGdukeneurosurg]

Know the ACLS Algorithm Primary medications

[The Heart @ZHeart11768530]

🔴 A Systematic Approach to Understanding Acid-Base Disorders in the Critically Ill #2023Review

https://t.co/RUqOKeB85o
#CardioEd #cardiotwitter #cardiology

[Jasmine Sethi @JasmineNephro]

🫘 Hypertension in CKD

Staging and management guidelines

@NDTsocial @hjanders_hans

https://t.co/8ljRGWE2an

[Scott Isaacs @scottisaacsmd]

There are significant reductions in HbA1c, BMI, and abdominal fat with intermittent fasting. #intermittentfasting https://t.co/ZiS8718oXA

[TheLiverDoc™ @theliverdoc]

Big news in the field of Hepatology

In 1980, Jurgen Ludwig and his colleagues at Mayo Clinic, identified a severe type of fatty liver disease in people who did not drink signficant amounts of alcohol. The disease was more common in women, most patients were obese and suffered from diabetes.

No journal would accept their findings and the new name they gave the disease at the time, for a very long time and the paper got rejected multiple times.

They called it NASH, short for non-alcoholic fatty liver disease - the most severe form of NAFLD - or non-alcoholic fatty liver disease. https://t.co/Og3vJ0WMfA

Forget the 3816 times the paper has been cited in medical literature since, but these two terms are so well-known and commonly used even among the non-medical community that it is argualby the most common-reason consultation in a liver outpatient clinic in the current era.

But the Hepatology societies thought the term was kind of stigmatizing - one, it centered around not using alcohol signficantly (alcoholic is not a nice term) and also impossed the term 'fatty' on patients, which was kind of "judgemental," with negativity.

Thus, a transparent and collaborative Nomenclature Development Initiative process was started in 2020 with multiple global hepatology and gastroenterology societies, patients and patient advocacy organizations, regulators and industry representatives. A total of 236 panellists from 56 countries participated in four online surveys and two hybrid meetings.

Yesterday, after almost 41 years in existence, the term NAFLD and NASH was retired.

The new kids on the block are here.
Please meet them.

It is no more fatty liver disease - it is steatotic liver disease or SLD

It is no more NAFLD - but MASLD or metabolic dysfunction-associated steatotic liver disease.
MASLD is identified when patients who have hepatic (liver) steatosis (at least 5% liver cells should have fat deposit) and have at least one of five cardiometabolic risk factors without signficant alcohol consumption.

Metabolic dysfunction-associated steatohepatitis (MASH) is the replacement term for NASH.

But what if they have alcohol consumption which is inbetween insignficant consumption and signficiant consumption?
New category: MetALD - to describe those with MASLD who consume greater amounts of alcohol per week (140 g/week and 210 g/week for females and males respectively).

Those with no metabolic parameters and no known cause have "cryptogenic SLD."

This seminal paper and the rigorous scientific method which was followed to come to new terminologies is now available to read for free in the influential journal @HEP_Journal #LiverTwitter #MedTwitter

Read more on it here: https://t.co/HjyZw8KdVJ

[Children's Mercy @ChildrensMercy]

She’s a Bluey-obsessed grade-schooler with a sunny disposition and an extraordinary story: Kenzie was born with #BiliaryAtresia & received a new liver earlier this year. Read her journey from late-onset jaundice to a successful #Transplant 7 years later: https://t.co/2OkFW7MNDT

[Muamar Amirullah @muamarray]

Marathon Runner Won't Let Allergy to Exercise Hold Her Back - ABC News via @ABC - https://t.co/d3ZowesOIM

[Vincent van Unen @VincentvUnen]

Grateful for the invitation at internal Medicine Department of Universitas Airlangga in Indonesia to give lectures on computational approaches in single-cell biology. Also, very fruitful discussions on international collaborations. Thank you! @GlobalLumc

[AC Milan @acmilan]

Who did you hug at the final whistle? 🤗
E voi chi avete abbracciato al fischio finale? 🤗
#MilanRoma #ANewMilan

[World Athletics @WorldAthletics]

It was 10 seconds that shook up the world of sprinting – 10.18 seconds, to be precise, the amount of time it took Lalu Muhammad Zohri to stun the superpowers and grab 100m gold at the IAAF World U20 Championships Tampere 2018.

Feature: https://t.co/4t70OZ26r1

[AC Milan @acmilan]

Full-Time / Fischio Finale 🔚
#CrotoneMilan 0-3
6' @KessieFranck ⚽️🔴⚫️
18' Cutrone ⚽️🔴⚫️
23' @suso30oficial ⚽️🔴⚫️